Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 858
Filtrar
1.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-782156

RESUMO

PURPOSE: To describe the 4-year metabolic follow-up results from the BLAST study.MATERIALS AND METHODS: Baseline hemoglobin A1c (HbA1c), weight, and waist circumference (WC) data were recorded in 185 men recruited for the BLAST randomised controlled trial (RCT) and erectile function (EF) scores were also available in an additional 48 men screened for the RCT. Intra/inter-group associations between these parameters and testosterone replacement therapy (TRT) were assessed at 1) end of the RCT (30 weeks), 2) open-label phase (82 weeks), and 3) final assessment via non-parametric statistics.RESULTS: Improvement in HbA1c and weight at the end of the RCT and open-label phase in men on TRT was not maintained long-term. The convergence in HbA1c could have been due to incentivised care with HbA1c targets. Interestingly those on TRT at final assessment required fewer anti-diabetic agents. The weight increase in routine care may have been due to changes in diabetes medication or an increase in lean muscle mass. WC continued to decrease in men on TRT indicating possible reduction in visceral fat. Improvement in EF scores continued with long-term TRT, this was abolished when TRT was discontinued.CONCLUSIONS: This study hints at benefits in glycaemic control, weight and WC, and long-term RCTs studying mechanisms of benefit and clinical outcomes are necessary. Our results also show that EF scores continued to improve with long-term TRT, even beyond the 6 months that we previously reported in the BLAST RCT.


Assuntos
Diabetes Mellitus Tipo 2 , Disfunção Erétil , Seguimentos , Humanos , Hipogonadismo , Gordura Intra-Abdominal , Masculino , Testosterona , Circunferência da Cintura
2.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-782154

RESUMO

PURPOSE: We evaluated the associations of metabolic syndrome (MetS) and its components with testosterone levels in the Korean population.MATERIALS AND METHODS: This cross-sectional study was performed among 6,967 adult (age≥20 years) men who attended health screening during 2006 to 2015. MetS was defined using the National Cholesterol Education Program Adult Treatment Panel III criteria. Associations were evaluated using unconditional logistic regression.RESULTS: The estimated age-adjusted prevalence of MetS in adult and middle-aged (≥40 years) Korean men was 27.5% and 30.6%, respectively. Quartile analysis showed that high serum testosterone levels were significantly associated with a low risk of MetS (highest vs. lowest quartile, odds ratio=0.528; p(trend)<0.001), with an approximately 13% reduction in MetS risk per 1 ng/mL increment of serum testosterone levels. After considering covariates such as age and body mass index (BMI), the reduction in MetS risk was attenuated but remained significant (7% reduced risk per 1 ng/mL). Testosterone levels were inversely correlated with all MetS components, including hyperglycemia (r=−0.041), increased body size (r=−0.093), increased triglyceride levels (r=−0.090), decreased high-density lipoprotein cholesterol levels (r=−0.030), and elevated blood pressure (r=−0.071, all p<0.05). Among them, elevated triglyceride levels and blood pressure were independently associated with low serum testosterone levels, even after adjustment for age and BMI.CONCLUSIONS: Serum testosterone levels were inversely associated with MetS in Korean men. This association was attenuated after adjustment for age and BMI but remained significant. Among MetS components, increased triglyceride levels and elevated blood pressure were independently associated with testosterone levels, regardless of obesity.


Assuntos
Adulto , Grupo com Ancestrais do Continente Asiático , Pressão Sanguínea , Índice de Massa Corporal , Tamanho Corporal , Colesterol , Estudos Transversais , Educação , Humanos , Hiperglicemia , Hipogonadismo , Lipoproteínas , Modelos Logísticos , Masculino , Programas de Rastreamento , Obesidade , Prevalência , Testosterona , Triglicerídeos
3.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-782149

RESUMO

We had six cases of patients who were treated with long-term testosterone replacement therapy (TRT) after high dose-rate (HDR) brachytherapy and androgen deprivation therapy for high-risk prostate cancer. All patients were given testosterone enanthate by intramuscular injection every 3 to 4 weeks. Blood biochemistry including prostate specific antigen (PSA) level was evaluated every 3 to 6 months after TRT, and radiological imaging was performed every 12 months. All patients had slight increases in PSA within the normal range and not indicative of biochemical recurrence. A sudden increase in PSA was observed in one patient, but it finally decreased. Aging male symptoms scale and various metabolic factors were improved by TRT in all of cases. Although adverse events included polycythemia in one patient, no patients experienced disease recurrence or progression during TRT. Our results suggest TRT for high risk-patients with HDR brachytherapy for prostate cancer may be beneficial and safe.


Assuntos
Envelhecimento , Bioquímica , Braquiterapia , Humanos , Hipogonadismo , Injeções Intramusculares , Masculino , Policitemia , Próstata , Antígeno Prostático Específico , Neoplasias da Próstata , Recidiva , Valores de Referência , Testosterona
4.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 29(4 (Supl)): 393-399, out.-dez. 2019. tab
Artigo em Português | LILACS (Américas) | ID: biblio-1047325

RESUMO

A testosterona, hormônio masculino com efeitos androgênicos e anabólicos, também exerce efeito sobre o leito vascular. Este hormônio promove vasodilatação através da liberação de óxido nítrico e modulação dos canais de cálcio que impacta a função endotelial. Em pacientes com doença arterial coronariana (DAC) e insuficiência cardíaca (IC), reduções nas concentrações de testosterona total (<300 ng/dL) estão relacionadas com maior mortalidade e severidade dessas doenças. Em pacientes com DAC, a reposição de testosterona (RT) tem relação com melhora do tônus vascular coronário e melhora do limiar de isquemia. Em pacientes com IC, os efeitos parecem estar mais relacionados à melhora da capacidade funcional, aumento na distância percorrida em testes funcionais, maior VO2máx, menor razão VE/VCO2, e melhora adicional da sensibilidade barorreflexa. No entanto, embora os efeitos da testosterona sobre o aumento de massa muscular e força muscular estejam bem estabelecidos na literatura, os efeitos dessa substância no sistema cardiovascular precisam ser elucidados. O aumento das concentrações de antígeno prostático específico da próstata tem sido constantemente discutido quando a RT é proposta no tratamento de pacientes com doenças cardiovasculares. Por se tratar de um hormônio com grande potencial anabólico, os efeitos do uso de quantidades suprafisiológicas de testosterona e seus análogos sobre as alterações cardiovasculares em jovens atletas têm sido estudados. Portanto, o objetivo dessa revisão é abordar os efeitos benéficos da RT em homens com hipogonadismo com DAC e IC, e mostrar os riscos relacionados com a prática indiscriminada do uso de anabolizantes em jovens sem deficiência de testosterona


Testosterone, the male hormone with androgenic and anabolic effects, also has an effect on the vascular bed. This hormone promotes vasodilation by releasing nitric oxide and calcium channel modulation that impacts endothelial function. In patients with coronary artery disease (CAD) and heart failure (HF), reductions in total testosterone concentrations (<300 ng/dL) are related to higher mortality and severity of these diseases. In patients with CAD, testosterone replacement (TR) is related to improved coronary vascular tone and improved ischemia threshold. In HF patients, the effects seem be more related to improved functional capacity, increased distance covered in functional tests, higher VO2max, lower LV/VCO2 ratio, and further improvement of baroreflex sensitivity. However, although the effects of testosterone on muscle mass gain and muscle strength are well established in the literature, the effects of testosterone on the cardiovascular system need to be elucidated. Increased prostate-specific prostate antigen concentrations have been constantly discussed when TR is proposed in the treatment of patients with cardiovascular disease. Because it is a hormone with great anabolic potential, the effects of supraphysiological amounts of testosterone and its analogues on cardiovascular disorders in young athletes have been studied. Therefore, the objective of this review is to address the beneficial effects of TR in men with hypogonadism with CAD and HF, and to show the risks related to anabolic steroids abuse in young people without testosterone deficiency


Assuntos
Testosterona , Doenças Cardiovasculares/terapia , Doença da Artéria Coronariana , Sistema Cardiovascular , Exercício Físico , Vasos Coronários , Insuficiência Cardíaca Diastólica , Hormônios , Hipogonadismo
5.
Diagn. tratamento ; 24(1): [16-20], jan -mar 2019. tab
Artigo em Português | LILACS (Américas) | ID: biblio-1005091

RESUMO

Descoberta e sintetizada na Alemanha na década de 1930, a testosterona foi utilizada em vários experimentos, além da reposição no hipogonadismo clinicamente diagnosticado. Seu uso aumentou nos anos 1970, principalmente na pesquisa clínica como contraceptivo masculino. Nos anos 1990, novas formulações foram disponibilizadas, mas emergiram dúvidas sobre a segurança da reposição, ensejando mais ensaios clínicos. Nas duas últimas décadas, sociedades médicas desenvolveram diretrizes, instituindo parâmetros de tratamento (níveis hormonais, resultados sintomáticos, monitoramento da segurança) e regulamentando a prescrição de testosterona. Recente publicação apresentou e discutiu as abordagens referentes à terapia com testosterona para homens, conforme atuais condutas adotadas por médicos dos Estados Unidos e da Europa. Na Europa, a motivação para a prescrição de testosterona está embasada no argumento de que a terapia de reposição beneficia o paciente, o que é apoiado por diretrizes. Nos Estados Unidos, o cenário varia: num extremo, reposição de testosterona sem testes prévios nem monitoramento terapêutico e pouca supervisão; no outro, testes laboratoriais extensivos e prescrição limitada. Duas diretrizes (da American Urological Association e da Endocrine Society) orientam sobre o uso adequado, mas não há controle formal. Apesar das diferenças entre o cenário europeu e o norte-americano, há semelhanças importantes: recomendações de diretrizes para que apenas homens com testosterona baixa e sinais/sintomas associados sejam candidatos ao tratamento, comprovação de eficácia clínica e segurança das terapias para serem aprovadas, práticas baseadas em evidências e opiniões de especialistas, melhora da qualidade de vida e longevidade, por meio de modelos financeiramente viáveis.


Assuntos
Humanos , Masculino , Testosterona , Estados Unidos , Tratamento Farmacológico , Europa (Continente) , Saúde do Homem , Hipogonadismo
6.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-763513

RESUMO

Klinefelter syndrome (KS) is characterized by small testes, gynecomastia, tall stature, and hypergonadotropic hypogonadism. This condition is associated with extra X chromosomes. It is well known that these aneuploidies predispose individuals to the development of several cancers. Moreover, there are many case reports that show KS patients to have a higher relative risk for the development of malignancy. However, incracranial germ cell tumor (ICGCT) associated with KS is very uncommon. Herein, we report delayed diagnosis of KS in a 15-year-old boy with ICGCT, embryonal carcinoma of the pineal gland, after multimodality treatment in Korea.


Assuntos
Adolescente , Aneuploidia , Carcinoma Embrionário , Diagnóstico Tardio , Ginecomastia , Humanos , Hipogonadismo , Síndrome de Klinefelter , Coreia (Geográfico) , Masculino , Neoplasias Embrionárias de Células Germinativas , Glândula Pineal , Testículo , Cromossomo X
7.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-785642

RESUMO

OBJECTIVE: We investigated the clinical characteristics of men with testosterone replacement therapy (TRT)-induced hypogonadism and its effect on assisted reproductive technology (ART) in infertile couples.METHODS: This study examined the records of 20 consecutive male patients diagnosed with azoospermia or severe oligozoospermia (<5×10⁶/mL) who visited a single infertility center from January 2008 to July 2018. All patients were treated at a primary clinic for erectile dysfunction or androgen deficiency symptoms combined with low serum testosterone. All men received a phosphodiesterase 5 inhibitor and TRT with testosterone undecanoate (Nebido®) or testosterone enanthate (Jenasteron®). Patients older than 50 years or with a chronic medical disease such as diabetes were excluded.RESULTS: The mean age of patients was 37 years and the mean duration of infertility was 16.3±11.6 months. At the initial presentation, eight patients had azoospermia, nine had cryptozoospermia, and three had severe oligozoospermia. Serum follicle-stimulating hormone levels were below 1.0 mIU/mL in most patients. Three ongoing ART programs with female factor infertility were cancelled due to male spermatogenic dysfunction; two of these men had normal semen parameters in the previous cycle. After withholding TRT, serum hormone levels and sperm concentrations returned to normal range after a median duration of 8 months.CONCLUSION: TRT with high-dose testosterone can cause spermatogenic dysfunction due to suppression of the hypothalamic-pituitary-testicular axis, with adverse effects on infertility treatment programs. TRT is therefore contraindicated for infertile couples attempting to conceive, and the patient's desire for fertility must be considered before initiation of TRT in a hypogonadal man.


Assuntos
Azoospermia , Nucleotídeo Cíclico Fosfodiesterase do Tipo 5 , Disfunção Erétil , Características da Família , Feminino , Fertilidade , Hormônio Foliculoestimulante , Humanos , Hipogonadismo , Infertilidade , Infertilidade Masculina , Masculino , Oligospermia , Valores de Referência , Técnicas de Reprodução Assistida , Sêmen , Espermatozoides , Testosterona
8.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-760650

RESUMO

OBJECTIVE: To elucidate the association between clinical and laboratory characteristics and pituitary magnetic resonance imaging (MRI) abnormalities in young female patients with hypogonadotropic hypogonadism (HH). METHODS: We retrospectively investigated a series of 74 female patients (age range, 14–42 years) with normoprolactinemic HH who underwent pituitary MRI. Pubertal milestones and hormonal features of patients with small pituitary glands (PGs) and space-occupying lesions were compared with those of patients with normal PGs. RESULTS: The overall frequency of abnormal PGs was 35.1%, with space-occupying lesions observed in 8 patients (10.8%), and small PG observed in 18 patients (24.3%). The mean serum gonadotropin level was not different between patients with and without pituitary MRI abnormalities (P>0.05). Space-occupying lesions were not associated with low gonadotropin levels, type of amenorrhea, or presence of secondary sex characteristics. The frequency of space-occupying lesions was higher in patients with interrupted puberty (25.0%) than in patients who did not go through puberty (4.8%) or had a normal puberty (9.8%), but were not statistically significant (P>0.05). Small PG was associated with low gonadotropin levels and type of amenorrhea (P<0.05). CONCLUSION: Clinically significant space-occupying lesions were not associated with low gonadotropin levels, type of amenorrhea, or presence of secondary sex characteristics. However, the frequency of space-occupying lesions was higher in patients with interrupted puberty than in patients who did not go through puberty or who with normal puberty.


Assuntos
Adolescente , Amenorreia , Feminino , Gonadotropinas , Humanos , Hipogonadismo , Imagem por Ressonância Magnética , Hipófise , Puberdade , Puberdade Tardia , Estudos Retrospectivos , Caracteres Sexuais
9.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-719632

RESUMO

A third of men with type 2 diabetes (T2DM) have hypogonadotrophic hypogonadism (HH) and associated increased risk of cardiovascular and all-cause mortality. Men with HH are at increased risk of developing incident T2DM. We conducted MEDLINE, EMBASE, and COCHRANE reviews on T2DM, HH, testosterone deficiency, cardiovascular and all-cause mortality from May 2005 to October 2017, yielding 1,714 articles, 52 clinical trials and 32 randomized controlled trials (RCT). Studies with testosterone therapy suggest significant benefits in sexual function, quality of life, glycaemic control, anaemia, bone density, fat, and lean muscle mass. Meta-analyses of RCT, rather than providing clarification, have further confused the issue by including under-powered studies of inadequate duration, multiple regimes, some discontinued, and inbuilt bias in terms of studies included or excluded from analysis.


Assuntos
Viés , Densidade Óssea , Doenças Cardiovasculares , Diabetes Mellitus Tipo 2 , Humanos , Hipogonadismo , Masculino , Mortalidade , Qualidade de Vida , Testosterona
10.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-719631

RESUMO

Testosterone has a variety of functions and is commonly used in older men to treat symptoms of hypogonadism, such as decreased libido, decreased mood and erectile dysfunction. Despite its positive effects on sexual function, it has a negative effect on fertility. Exogenous testosterone therapy can negatively affect the hypothalamic-pituitary gonadal axis and inhibit the production of follicle stimulating hormone and luteinizing hormone. The purpose of this review is to discuss the contraceptive properties of testosterone therapy and to discuss strategies to increase testosterone in men with the desire to preserve fertility.


Assuntos
Anticoncepção , Disfunção Erétil , Serviços de Planejamento Familiar , Fertilidade , Hormônio Foliculoestimulante , Gônadas , Humanos , Hipogonadismo , Infertilidade , Libido , Hormônio Luteinizante , Masculino , Testosterona
11.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-719626

RESUMO

PURPOSE: To characterize the population of hypogonadal men who presented to a tertiary academic urology clinic and evaluate risk factors for primary vs. secondary hypogonadism. MATERIALS AND METHODS: We evaluated all men with International Classification of Diseases-9 diagnosis codes R68.82 and 799.81 for low libido, 257.2 for testicular hypofunction, and E29.1 for other testicular hypofunction at a tertiary academic medical center from 2013 to 2017. We included men who had testosterone (T) and luteinizing hormone (LH) drawn on the same day. We classified men based on T and LH levels into eugonadal, primary, secondary, and compensated hypogonadism. Risk factors including age, body mass index (BMI) over 30 kg/m2, current smoking status, alcohol use greater than 5 days per week, and Charlson comorbidity index greater than or equal to 1 were investigated and measured in each group using the eugonadal group for reference. RESULTS: Among the 231 men who had both T and LH levels, 7.4%, 42.4%, and 7.4% were classified as primary, secondary, and compensated hypogonadism, respectively. Only elevated BMI was associated with secondary hypogonadism compared to eugonadal men (median BMI, 30.93 kg/m2 vs. 27.69 kg/m2, p=0.003). BMI, age, comorbidities, smoking, or alcohol use did not appear to predict diagnosis of secondary hypogonadism. CONCLUSIONS: Secondary hypogonadism appears to be the most common cause of hypogonadism among men complaining of low T and decreased libido at a tertiary academic medical center. Secondary hypogonadism is associated with elevated BMI and therefore obesity should be used as a marker to evaluate men for both T and LH levels.


Assuntos
Centros Médicos Acadêmicos , Índice de Massa Corporal , Classificação , Clomifeno , Comorbidade , Diagnóstico , Humanos , Hipogonadismo , Libido , Hormônio Luteinizante , Masculino , Obesidade , Fatores de Risco , Fumaça , Fumar , Centros de Atenção Terciária , Testosterona , Urologia
12.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-719624

RESUMO

PURPOSE: Testosterone replacement therapy is an effective treatment for late-onset hypogonadism (LOH) despite a few contraindications and side-effects. The aim of this study was to determine whether modified Ojayeonjonghwan (KH-204, Korean herbal formula) improved LOH. KH-204 is a strong antioxidant herbal formula. We evaluated the effect of Korean herbal prescription on androgen receptor (AR) expression in an aged rat model of LOH. MATERIALS AND METHODS: Eighteen-month-old rats were used as aged LOH rat models. Eighteen Sprague-Dawley rats were randomly divided into three equal groups of six animals each and treated with one of the following: 1) normal control group (oral administration with distilled water, n=6), 2) KH-204 200 group (oral administration with 200 mg/kg of KH-204, n=6), and 3) KH-204 400 group (oral administration with 400 mg/kg of KH-204, n=6). After four weeks of treatment (once daily, distilled water or KH-204), serum testosterone levels, changes in testicular and epididymal weight, Western blotting analysis of AR expression and measurement of oxidative stress were examined. RESULTS: Treatment with the herbal formulation KH-204 200 mg/kg and 400 mg/kg (1) increased the weights of testis and epididymis; (2) increased the level of serum testosterone; (3) increased the level of superoxide dismutase and reduced the level of 8-hydroxy-20-deoxyguanosine; and (4) upregulated AR expression in testicular tissue. CONCLUSIONS: KH-204 might be an effective alternative for LOH. It improves antioxidant mechanisms and increases testicular AR expression without side-effects.


Assuntos
Envelhecimento , Animais , Western Blotting , Epididimo , Hipogonadismo , Masculino , Modelos Animais , Estresse Oxidativo , Fitoterapia , Prescrições , Ratos , Ratos Sprague-Dawley , Receptores Androgênicos , Superóxido Dismutase , Testículo , Testosterona , Água , Pesos e Medidas
13.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-719372

RESUMO

Obstructive sleep apnea (OSA) is a common disorder characterized by intermittent hypoxia and sleep fragmentation. OSA in middle-aged men is often associated with decreased testosterone secretion, together with obesity and aging. Although OSA treatment does not reliably increase testosterone levels in most studies, OSA treatment with testosterone replacement therapy (TRT) may not only improve hypogonadism, but can also alleviate erectile/sexual dysfunction. However, because TRT may exacerbate OSA in some patients, patients should be asked about OSA symptoms before and after starting TRT. Furthermore, TRT should probably be avoided in patients with severe untreated OSA.


Assuntos
Envelhecimento , Hipóxia , Pressão Positiva Contínua nas Vias Aéreas , Disfunção Erétil , Humanos , Hipogonadismo , Masculino , Neoplasia Endócrina Múltipla Tipo 1 , Obesidade , Disfunções Sexuais Fisiológicas , Apneia Obstrutiva do Sono , Privação do Sono , Testosterona
14.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-742355

RESUMO

PURPOSE: To determine the role of metabolic syndrome (MetS) as a risk factor for acquired premature ejaculation (PE) after considering the various risk factors, such as lower urinary tract symptoms, erectile dysfunction, hypogonadism, and prostatitis. MATERIALS AND METHODS: From January 2012 to January 2017, records of 1,029 men were analyzed. We performed multivariate analysis to identify risk factors for PE, including the covariate of age, marital status, International Prostate Symptom Score, International Index of Erectile Function (IIEF) score, National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) score, serum testosterone levels, and all components of MetS. Acquired PE was defined as self-reported intravaginal ejaculation latency time ≤3 minutes, and MetS was diagnosed using the modified National Cholesterol Education Program Adult Treatment Panel III criteria. RESULTS: Of 1,029 men, 74 subjects (7.2%) had acquired PE and 111 (10.8%) had MetS. Multivariate analysis showed that the IIEF overall satisfaction score (odds ratio [OR]=0.67, p<0.001), NIH-CPSI pain score (OR=1.07, p=0.035), NIH-CPSI voiding score (OR=1.17, p=0.032), and presence of MetS (OR=2.20, p=0.022) were significantly correlated with the prevalence of acquired PE. In addition, the Male Sexual Health Questionnaire for Ejaculatory Dysfunction scores and ejaculation anxiety scores progressively decreased as the number of components of MetS increased. CONCLUSIONS: MetS may be an independent predisposing factor for the development of acquired PE. Effective prevention and treatment of MetS could also be important for the prevention and treatment of acquired PE.


Assuntos
Academias e Institutos , Adulto , Ansiedade , Causalidade , Colesterol , Educação , Ejaculação , Disfunção Erétil , Humanos , Hipogonadismo , Sintomas do Trato Urinário Inferior , Masculino , Estado Civil , Análise Multivariada , Obesidade , Ejaculação Precoce , Prevalência , Próstata , Prostatite , Saúde Reprodutiva , Fatores de Risco , Testosterona
15.
Rev. Hosp. Niños B.Aires ; 60(270): 214-222, sept. 2018.
Artigo em Espanhol | LILACS (Américas) | ID: biblio-998451

RESUMO

Introducción: La capacidad funcional del testículo en los niños con criptorquidia ha recibido poca atención. La hormona anti-mülleriana (AMH), producida por la célula de Sertoli, es el marcador ideal para evaluar la función testicular durante la infancia. Objetivo: Caracterizar la función testicular en niños prepuberales antes de la orquidopexia. Investigar la asociación entre función testicular y las características de la criptorquidia. Pacientes y métodos: Estudio de corte transversal y analítico, retrospectivo. Medida de resultado principal: concentración de AMH. Medidas de resultados secundarias: concentraciones de gonadotrofinas y testosterona. Para comparación, se utilizaron los niveles hormonales de 179 niños normales. Resultados: Se seleccionaron 186 pacientes con criptorquidia bilateral y 124 con criptorquidia unilateral. La mediana de SDS de AMH fue menor a 0 en ambos grupos. La concentración sérica de AMH fue más baja en pacientes con criptorquidia bilateral que en niños controles y en niños con criptorquidia unilateral. La testosterona estuvo disminuida en niños menores de 6 meses. Las gonadotrofinas estuvieron aumentadas en un bajo porcentaje de los casos. Conclusión: Los niños prepuberales con criptorquidia, especialmente aquellos con criptorquidia bilateral, tienen menor producción de AMH y una considerable prevalencia de disfunción testicular


Introduction: Little information is available on testicular function in boys with cryptorchidism. Anti-müllerian hormone (AMH) is a good marker of testicular functionin childhood. Objective: the aim of this study was to assess testicular function in boys with cryptorchidism before orchiopexy, and to look for an association between testicular function and features of cryptorchidism. Patients and methods: We performed a cross-sectional, retrospective study. Main outcome measure was serum AMH concentration, and secondary variables were gonadotropin and testosterone concentrations. For comparison, levels in 179 normal boys were compared. Results: 186 boys with bilateral cryptorchidism and 124 with unilateral cryptorchidism were included. Mean SDS AMH was below 0 in both groups. Mean serum AMH was lower in boys with bilateral cryptorchidism, as compared to unilateral cryptorchidism and controls between 6 months and 8.9 years of age. Testosterone was lower than normal in boys < 6 months of age. Gonadotropins were rarely affected. Conclusions: Prepubertal boys with cryptorchidism, especially those with bilateral forms, have a lower AMH production, reflecting testicular dysfunction


Assuntos
Masculino , Criptorquidismo , Gonadotropinas , Hipogonadismo , Pediatria , Células de Sertoli , Testosterona
16.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wprim-776692

RESUMO

Kallmann syndrome (KS) is a rare pediatric disease with major manifestations of olfactory dysfunction and hypogonadotropic hypogonadism. Five children (4 boys and 1 girl) with KS reported in this article were aged between 6 months and 19 years at the time when they attended the hospital. All the children had the clinical manifestation of hypogonadotropic hypogonadism; in addition, three children had olfactory dysfunction (two were found to have olfactory bulb dysplasia on magnetic resonance imaging), one had cleft lip and palate, and one had micropenis and cryptorchidism with right renal agenesis during infancy. All the five children had normal karyotype and their parents had normal clinical phenotypes. The uncle of one child had underdeveloped secondary sexual characteristics and olfactory disorder since childhood. High-throughput sequencing found two known heterozygous missense mutations in the FGFR1 gene, i.e., c.1097C>T(p.P366L) and c.809G>C(p.G270A), in two children. One child had a novel frameshift mutation, c.1877_1887/p.S627Tfs*6, in the KAL1 gene; this deletion mutation caused a frameshift in base sequence and produced truncated proteins, which led to a significant change in protein structure, and thus it was highly pathogenic. It is concluded that KS has great clinical and genetic heterogeneity and can be accompanied by incomplete dominant inheritance and that gene detection helps with the diagnosis of this disease.


Assuntos
Adolescente , Criança , Pré-Escolar , Análise Mutacional de DNA , Proteínas da Matriz Extracelular , Feminino , Heterozigoto , Humanos , Hipogonadismo , Lactente , Síndrome de Kallmann , Masculino , Mutação , Proteínas do Tecido Nervoso , Receptor Tipo 1 de Fator de Crescimento de Fibroblastos , Adulto Jovem
17.
Anatomy & Cell Biology ; : 284-291, 2018.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-718951

RESUMO

The role of androgens in the development of cardiovascular diseases remains controversial. The current study therefore sought to determine the changes in the histomorphology of the common carotid artery of the male rat in orchidectomy-induced hypogonadism. Twenty-two Rattus norvegicus male rats aged 2 months were used. The rats were randomly assigned into baseline (n=4), experimental (n=9), and control (n=9) groups. Hypogonadism was surgically induced in the experimental group by bilateral orchiectomy under local anesthesia. At experiment weeks 3, 6, and 9, three rats from each group (experimental and control) were euthanized, their common carotid artery harvested, and routine processing was done for paraffin embedding, sectioning, and staining. The photomicrographs were taken using a digital photomicroscope for morphometric analysis. Orchidectomy resulted in the development of vascular fibrosis, with a significant increase in collagen fiber density and decrease in smooth muscle and elastic fiber density. Moreover, there was development of intimal hyperplasia, with fragmentation of medial elastic lamellae in the common carotid artery of the castrated rats. Orchidectomy induces adverse changes in structure of the common carotid artery of the male rat. These changes may impair vascular function, therefore constituting a possible structural basis for the higher incidences of cardiovascular diseases observed in hypogonadism.


Assuntos
Androgênios , Anestesia Local , Animais , Doenças Cardiovasculares , Artéria Carótida Primitiva , Colágeno , Tecido Elástico , Fibrose , Humanos , Hiperplasia , Hipogonadismo , Incidência , Masculino , Músculo Liso , Orquiectomia , Inclusão em Parafina , Ratos
18.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-717065

RESUMO

X-linked adrenal hypoplasia congenita (AHC) is a rare disorder that usually presents clinically as adrenal insufficiency in early infancy. It is caused by mutations in the NR0B1 gene which is located on the short arm of chromosome X (Xp21). The NR0B1 gene plays an important role in normal development and function of both the adrenal and gonadal axes and some patients with the disease can present in adolescence with hypogonadotropic hypogonadism. Testicular microlithiasis is an ultrasonographic finding of unknown etiology that has been associated with several benign conditions such as cryptorchidism, congenital adrenal hyperplasia, varicoceles, and testicular malignancy. We report the case of an 11-year-old boy who was diagnosed at the age of 8 months with X-linked AHC due to adrenal failure and presented testicular microlithiasis during follow-up. To the best of our knowledge, this is the first case of an X-linked AHC patient diagnosed with testicular microlithiasis in follow-up.


Assuntos
Adolescente , Hiperplasia Suprarrenal Congênita , Insuficiência Adrenal , Braço , Criança , Criptorquidismo , Seguimentos , Gônadas , Humanos , Hipogonadismo , Masculino , Varicocele
19.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-716915

RESUMO

Lower urinary tract function is modulated by neural, vascular and urethral and bladder structural elements. The pathophysiological mechanisms of lower urinary tract symptoms (LUTS) encompass prostate enlargement, alterations in urethra histological structure bladder fibrosis and alterations in pelvic neuronal and vascular networks, The complex pathophysiological relationship between testosterone (T) deficiency (TD) and the constellations LUTS, and metabolic dysfunction manifested in the metabolic syndrome (Met S) remains poorly understood. TD has emerged as one the potential targets by which Met S may contribute to the onset and development as well as worsening of LUTS. Because it has been recognized that treatment of men with Met S with T therapy ameliorates Met S components, it is postulated that T therapy may represent a therapeutic target in improving LUTS. Furthermore, the effect of TD on the prostate remains unclear, and often debatable. It is believed that T exclusively promotes prostate growth, however recent evidence has strongly contradicted this belief. The true relationship between benign prostatic hyperplasia, TD, and LUTS remains elusive and further research will be required to clarify the role of T in both benign prostatic hypertrophy (BPH) and LUTS as a whole. Although there is conflicting evidence about the benefits of T therapy in men with BPH and LUTS, the current body of literature supports the safety of using this therapy in men with enlarged prostate. As the population afflicted with obesity epidemic continues to age, the number of men suffering from Met S and LUTS together is expected to increase.


Assuntos
Fibrose , Humanos , Hipogonadismo , Sintomas do Trato Urinário Inferior , Masculino , Neurônios , Obesidade , Próstata , Hiperplasia Prostática , Testosterona , Uretra , Bexiga Urinária , Sistema Urinário
20.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wprim-716913

RESUMO

PURPOSE: The aim of this study was to investigate the efficacy and safety of a mixed extract of Trigonella foenum-graecum seed and Lespedeza cuneata (TFGL) for the treatment of testosterone deficiency syndrome (TDS). MATERIALS AND METHODS: Patients were instructed to take a placebo or 200 mg TFGL capsule twice per day for 8 weeks. The primary efficacy variable was the change from baseline in the Aging Males' Symptoms scale (AMS), as well as levels of serum total and free testosterone. Secondary efficacy measurements included changes from baseline in the number of ‘yes’ answers on the Androgen Deficiency in the Aging Male (ADAM) questionnaire, levels of serum total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglyceride, all domain scores of the International Index of Erectile Function (IIEF), perceived stress scale-10 (PSS-10), as well as changes in body composition. RESULTS: The TFGL group exhibited a significant improvement in the AMS scores at 8 weeks, total testosterone at 8 weeks, and free testosterone at 4 and 8 weeks. At 4 weeks, 25% of the TFGL group changed to negative in terms of ADAM scores and 34.1% of the TFGL group had negative scores at the end of the study. The TFGL group exhibited a significant improvement in total cholesterol, HDL-C, LDL-C, triglyceride, IIEF scores, and PSS-10 scores at 8 weeks. CONCLUSIONS: The mixed extract of TFGL resulted in significant improvements in symptoms of TDS, as measured by the AMS, ADAM, PSS-10 and testosterone levels.


Assuntos
Envelhecimento , Composição Corporal , Colesterol , HDL-Colesterol , LDL-Colesterol , Medicina Herbária , Humanos , Hipogonadismo , Lespedeza , Masculino , Fitoterapia , Testosterona , Triglicerídeos , Trigonella
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA